Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company

Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization

Fineline Cube May 11, 2024

US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...

Company Deals

Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion

Fineline Cube May 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...

Policy / Regulatory

China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront

Fineline Cube May 11, 2024

The State Council of China has released its annual legislative work plan for 2024, outlining...

Company Drug

MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint

Fineline Cube May 10, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip

Fineline Cube May 10, 2024

Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...

Company Drug

WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light

Fineline Cube May 10, 2024

WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...

Company Drug

RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial

Fineline Cube May 10, 2024

Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...

Company Deals Drug

BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody

Fineline Cube May 10, 2024

Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...

Company Drug

China Grants Marketing Nod to Ferring Pharmaceuticals’ Rekovelle for Assisted Reproduction

Fineline Cube May 10, 2024

Switzerland-based Ferring Pharmaceuticals Ltd announced that its recombinant human follicle stimulating hormone δ injection, Rekovelle,...

Policy / Regulatory

Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation

Fineline Cube May 10, 2024

Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...

Company Drug

Chia Tai Tianqing’s PD-L1 Antibody Benmelstobart Wins NMPA Nod for ES-SCLC

Fineline Cube May 10, 2024

China-based Chia Tai Tianqing has announced that it has received marketing approval from the National...

Company

GSK Shakes Up Leadership with Promotion of Cecilia Qi and Appointment of Sherman Yu

Fineline Cube May 10, 2024

Mike Crichton, Senior Vice President of GlaxoSmithKline (GSK, NYSE: GSK) for the Greater China and...

Company Drug

Sichuan Biokin Pharmaceutical Advances BL-B16D1 to Clinical Trial for Advanced Solid Tumors

Fineline Cube May 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...

Company Drug

Bio-Thera Solutions’ PD-1 and ADC Combo Gets NMPA Approval for Clinical Trial in Solid Tumors

Fineline Cube May 10, 2024

Bio-Thera Solutions, Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sandoz Q1 2024 Results Highlight 6% Growth, Led by Biosimilars and European Strength

Fineline Cube May 10, 2024

Switzerland-based Sandoz (SWX: SDZ) has reported its financial results for the first quarter of 2024,...

Company Drug

Jiangsu QYuns Therapeutics Gets NMPA Green Light for CSU Treatment QX013N

Fineline Cube May 10, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...

Company Medical Device

MicroPort MedBot’s Toumai Robot Gets EU Green Light for Broad Surgical Applications

Fineline Cube May 10, 2024

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its Toumai endoscopic surgery...

Company Medical Device

MicroPort CardioFlow Medtech’s AltaValve Receives FDA Breakthrough Designation for Mitral Regurgitation Treatment

Fineline Cube May 10, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced...

Company Drug

Laekna’s ActRIIA Monoclonal Antibody LAE102 Gets Green Light from China’s CDE for Obesity Treatment

Fineline Cube May 10, 2024

Sino-US biotech firm Laekna has announced that it has received clinical trial approval from the...

Company Deals

Cancer Diagnostics Firm Mirxes Aims for USD 100 Million in Hong Kong IPO

Fineline Cube May 10, 2024

Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the...

Posts pagination

1 … 355 356 357 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.